CA3076022C - Chromane monobactam compounds for the treatment of bacterial infections - Google Patents
Chromane monobactam compounds for the treatment of bacterial infections Download PDFInfo
- Publication number
- CA3076022C CA3076022C CA3076022A CA3076022A CA3076022C CA 3076022 C CA3076022 C CA 3076022C CA 3076022 A CA3076022 A CA 3076022A CA 3076022 A CA3076022 A CA 3076022A CA 3076022 C CA3076022 C CA 3076022C
- Authority
- CA
- Canada
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566779P | 2017-10-02 | 2017-10-02 | |
| US62/566,779 | 2017-10-02 | ||
| PCT/US2018/053039 WO2019070492A1 (en) | 2017-10-02 | 2018-09-27 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3076022A1 CA3076022A1 (en) | 2019-04-11 |
| CA3076022C true CA3076022C (en) | 2023-01-17 |
Family
ID=65994576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076022A Active CA3076022C (en) | 2017-10-02 | 2018-09-27 | Chromane monobactam compounds for the treatment of bacterial infections |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11433055B2 (https=) |
| EP (1) | EP3691639B1 (https=) |
| JP (1) | JP7252948B2 (https=) |
| KR (1) | KR102425959B1 (https=) |
| CN (2) | CN111201021B (https=) |
| AU (1) | AU2018345523B2 (https=) |
| CA (1) | CA3076022C (https=) |
| CL (1) | CL2020000860A1 (https=) |
| CO (1) | CO2020004087A2 (https=) |
| CR (1) | CR20200148A (https=) |
| DO (1) | DOP2020000058A (https=) |
| EA (1) | EA202090604A1 (https=) |
| ES (1) | ES2968467T3 (https=) |
| GE (2) | GEP20227406B (https=) |
| IL (1) | IL273306B (https=) |
| JO (1) | JOP20200130B1 (https=) |
| MA (1) | MA50629A (https=) |
| MX (1) | MX2020003581A (https=) |
| NI (1) | NI202000023A (https=) |
| PE (1) | PE20201256A1 (https=) |
| PH (1) | PH12020550107A1 (https=) |
| SA (1) | SA520411571B1 (https=) |
| SG (1) | SG11202002575UA (https=) |
| UA (1) | UA126000C2 (https=) |
| WO (1) | WO2019070492A1 (https=) |
| ZA (1) | ZA202001721B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156697B (zh) * | 2019-05-30 | 2022-05-06 | 常州沃腾化工科技有限公司 | 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法 |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022120048A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| AU2021473165B2 (en) * | 2021-11-09 | 2025-05-22 | Guangzhou HC New Drug Research Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF |
| CR20240212A (es) * | 2021-11-18 | 2024-07-01 | Merck Sharp & Dohme Llc | Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas |
| JP7671398B2 (ja) * | 2021-11-18 | 2025-05-01 | メルク・シャープ・アンド・ドーム・エルエルシー | クロマンアミジンモノバクタム抗生物質 |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| WO2024019916A2 (en) * | 2022-07-18 | 2024-01-25 | Merck Sharp & Dohme Llc | Chromane amidine monobactam compounds for the treatment of bacterial infections |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| US5250691A (en) * | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
| WO2007065288A2 (en) | 2005-12-07 | 2007-06-14 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| EP1938822A1 (en) * | 2006-12-21 | 2008-07-02 | Novartis AG | Combination therapy for the treatment of airways disease |
| BR112013008765B8 (pt) | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| AU2011336209B2 (en) | 2010-11-29 | 2015-03-19 | Pfizer Inc. | Monobactams |
| UY34585A (es) | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| PL2857039T3 (pl) | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| AP2016009374A0 (en) | 2014-03-24 | 2016-08-31 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| DK3212189T3 (da) * | 2014-10-31 | 2020-10-26 | Abbvie Overseas Sarl | Substituerede chromaner og fremgangsmåde til anvendelse deraf |
| FR3031423B1 (fr) * | 2015-01-06 | 2018-11-30 | Centre National De La Recherche Scientifique | Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif |
| CA3008006C (en) * | 2015-12-15 | 2024-04-09 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| KR102408800B1 (ko) * | 2016-03-07 | 2022-06-13 | 머크 샤프 앤드 돔 코포레이션 | 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법 |
-
2018
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 ES ES18864229T patent/ES2968467T3/es active Active
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/en not_active Ceased
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/en active Active
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 GE GEAP202215303A patent/GEAP202215303A/en unknown
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 CA CA3076022A patent/CA3076022C/en active Active
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 CN CN201880064269.2A patent/CN111201021B/zh active Active
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active Active
- 2018-09-27 CN CN202410563311.2A patent/CN118496221A/zh active Pending
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
-
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-19 SA SA520411571A patent/SA520411571B1/ar unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown
- 2020-05-28 JO JOJO/P/2020/0130A patent/JOP20200130B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3076022C (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| AU2017228870B2 (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
| JP7184646B2 (ja) | ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法 | |
| WO2012177707A1 (en) | Phosphate esters of gyrase and topoisomerase inhibitors | |
| JP7213173B2 (ja) | カルバペネム化合物 | |
| CA3233328A1 (en) | Lpxc inhibitors and uses thereof | |
| HK40029711A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| HK40029711B (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| WO2026043829A1 (en) | Chromane cyclic amidine monobactam compounds for the treatment of bacterial infections | |
| BR112020006381B1 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| EA044287B1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций | |
| WO2000015640A1 (en) | Carbapenem compounds | |
| BR112018068462B1 (pt) | Composto, e, composição farmacêutica | |
| BR112018010962B1 (pt) | Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200317 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250811 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |